A Phase 1 interventional study of Cilostazol 50 mg Tablets and Cilostazol (Pletal®) 50 mg Tablets in Therapeutic Equivalency, Healthy, sponsored by Mutual Pharmaceutical Company, Inc.. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-12-22.
Sponsored by Mutual Pharmaceutical Company, Inc. · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of cilostazol tablets to an equivalent dose of Pletal® (cilostazol) tablets after a single oral dose administered under fasting conditions.
The purpose of this study is to evaluate and compare the relative bioavailability of a test formulation of cilostazol tablets to an equivalent dose of Pletal® (cilostazol) tablets after a single oral dose administered under fasting conditions. Thirty-two non-smoking, non-obese, healthy male and female volunteers between the ages of 18 and 55 will be randomly assigned in a crossover fashion to receive each of two cilostazol dosing regimens in sequence with a 7 day washout period between dosing periods. On the morning of Day 1, after an overnight fast of at least 10 hours, subjects will receive either a single oral dose of the test formulation, cilostazol (2 x 50 mg tablets), or a single oral dose of the reference formulation, Pletal® (2 x 50 mg tablets). After a 7 day washout period on the morning of Day 8, following an overnight fast of at least 10 hours, subjects will receive the alternate regimen. Blood samples will be drawn from all participants before dosing and for 24 hours post-dose on a confined basis at times sufficient to adequately define the pharmacokinetics of cilostazol. Blood sampling will then continue on a non-confined basis at 36 and 48 hours post-dose. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Subjects will be monitored throughout the confinement portion of the study for adverse reactions to the study drug and/or procedures. Blood pressure and pulse will be measured before dosing and at 3 and 24 hours post-dose. All adverse events whether elicited by query, spontaneously reported, or observed by clinic staff will be evaluated by the investigator and reported in the subject's case report form.
Mutual Pharmaceutical Company, Inc. is the lead sponsor of 44 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours.
Drug: Cilostazol 50 mg Tablets
A single dose of Cilostazol (Pletal® tablets, 2 x 50 mg ) administered after an overnight fast of at least 10 hours.
Drug: Cilostazol (Pletal®) 50 mg Tablets
Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
Also known as: Pletal®
Maximum Plasma Concentration (Cmax)
The maximum or peak concentration that cilostazol (test and reference product) reaches in the plasma.
Time frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 16, 24, 36 and 48 hours after drug administration.
Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule.
Time frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 16, 24, 36 and 48 hours after drug administration.
Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]
The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.
Time frame: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 12, 16, 24, 36 and 48 hours after drug administration.
Thirty-two healthy adult male and female volunteers from the community-at-large were enrolled.
| Milestone | Cilostazol 50 mg Tablets Then Pletal® 50 mg Tablets | Pletal® 50 mg Tablets Then Cilostazol 50 mg Tablets |
|---|---|---|
| Started | 16 | 16 |
| Completed | 16 | 16 |
| Not completed | 0 | 0 |
| Milestone | Cilostazol 50 mg Tablets Then Pletal® 50 mg Tablets | Pletal® 50 mg Tablets Then Cilostazol 50 mg Tablets |
|---|---|---|
| Started | 16 | 16 |
| Completed | 14 | 15 |
| Not completed | 2 | 1 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Cilostazol 50 mg Tablets Then Pletal® 50 mg Tablets | Pletal® 50 mg Tablets Then Cilostazol 50 mg Tablets |
|---|---|---|
| Started | 14 | 15 |
| Completed | 14 | 15 |
| Not completed | 0 | 0 |
The maximum or peak concentration that cilostazol (test and reference product) reaches in the plasma.
| ng/mL | Cilostazol 50 mg Tablets | Pletal® 50 mg Tablets |
|---|---|---|
| Maximum Plasma Concentration (Cmax) | 565.52 ± 155.67 | 570.60 ± 174.72 |
The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule.
| ng-hr/mL | Cilostazol 50 mg Tablets | Pletal® 50 mg Tablets |
|---|---|---|
| Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] | 7,265.38 ± 1,975.87 | 7,354.03 ± 2,048.83 |
The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.
| ng-hr/mL | Cilostazol 50 mg Tablets | Pletal® 50 mg Tablets |
|---|---|---|
| Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)] | 8,641.26 ± 3,010.04 | 8,706.54 ± 3,142.36 |
Collected over All adverse events were recorded during the 14 day course of the study.. Non-serious events are listed at a 3.22% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cilostazol 50 mg Tablets | — | 0/31 (0%) | 10/31 (32.3%) |
| Pletal® 50 mg Tablets | — | 0/30 (0%) | 12/30 (40%) |
| Event | Cilostazol 50 mg Tablets | Pletal® 50 mg Tablets |
|---|---|---|
| HeadacheNervous system disorders | 6/31 | 5/30 |
| HematuriaRenal and urinary disorders | 0/31 | 2/30 |
| BradycardiaCardiac disorders | 0/31 | 1/30 |
| TachycardiaCardiac disorders | 1/31 | 1/30 |
| NauseaGastrointestinal disorders | 0/31 | 1/30 |
| AnemiaBlood and lymphatic system disorders | 0/31 | 1/30 |
| Anemia hypochromBlood and lymphatic system disorders | 0/31 | 1/30 |
| AlbuminuriaMetabolism and nutrition disorders | 0/31 | 1/30 |
| HyperglycemiaMetabolism and nutrition disorders | 1/31 | 1/30 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/31 | 1/30 |
| Age, Categorical(Participants) | Cilostazol 50 mg Tablets and Pletal® 50 mg Tablets |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 32 |
| >=65 years | 0 |
| Age Continuous(years) | Cilostazol 50 mg Tablets and Pletal® 50 mg Tablets |
|---|---|
| Mean | 32.25 ± 11.98 |
| Sex: Female, Male(Participants) | Cilostazol 50 mg Tablets and Pletal® 50 mg Tablets |
|---|---|
| Female | 14 |
| Male | 18 |
| Race (NIH/OMB)(Participants) | Cilostazol 50 mg Tablets and Pletal® 50 mg Tablets |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 26 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
No study locations are listed for this record.
The record gives a start of Jun 2004, a primary completion of Jul 2004 and a completion of Jul 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilostazol
Mutual Pharmaceutical Company, Inc. →